{"id":744977,"date":"2014-05-19T16:00:00","date_gmt":"2014-05-19T16:00:00","guid":{"rendered":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-and-endocyte-announce-withdrawal-of-conditional-marketing-authorization-applications-for-vintafolide-and-companion-imaging-components-etarfolatide-and-intravenous-iv-folic-acid-in-europe\/"},"modified":"2023-03-22T00:04:55","modified_gmt":"2023-03-22T04:04:55","slug":"merck-and-endocyte-announce-withdrawal-of-conditional-marketing-authorization-applications-for-vintafolide-and-companion-imaging-components-etarfolatide-and-intravenous-iv-folic-acid-in-europe","status":"publish","type":"news_item","link":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-and-endocyte-announce-withdrawal-of-conditional-marketing-authorization-applications-for-vintafolide-and-companion-imaging-components-etarfolatide-and-intravenous-iv-folic-acid-in-europe\/","title":{"rendered":"Merck and Endocyte Announce Withdrawal of Conditional Marketing Authorization Applications for Vintafolide and Companion Imaging Components, Etarfolatide and Intravenous (IV) Folic Acid in Europe"},"content":{"rendered":"<p>WHITEHOUSE STATION, N.J. &#038; WEST LAFAYETTE, Ind.&#8211;(<a target=\"_blank\" href=\"http:\/\/www.businesswire.com\" rel=\"noopener\">BUSINESS WIRE<\/a>)&#8211;Merck (NYSE:MRK), known as MSD outside the United States and Canada, and<br \/>\n      Endocyte, Inc. (NASDAQ:ECYT), today announced the withdrawal of<br \/>\n      conditional marketing authorization applications (CMA) from the European<br \/>\n      Medicines Agency (EMA) for vintafolide and companion imaging components,<br \/>\n      imaging agent etarfolatide and intravenous (IV) folic acid, for the<br \/>\n      treatment of adult patients with folate receptor-positive,<br \/>\n      platinum-resistant ovarian cancer, in combination with pegylated<br \/>\n      liposomal doxorubicin (PLD).\n    <\/p>\n<p>\n      The Companies\u2019 decision was based on further review of interim data from<br \/>\n      the PROCEED trial. Study enrollment was suspended earlier this month<br \/>\n      based on the Data Safety Monitoring Board\u2019s (DSMB) recommendation that<br \/>\n      the study be stopped because vintafolide in combination with PLD versus<br \/>\n      PLD alone did not meet the pre-specified criteria for progression-free<br \/>\n      survival to allow continuation of the study. The DSMB did not identify<br \/>\n      any safety concerns for the patients enrolled in the PROCEED trial. The<br \/>\n      Companies will take steps to terminate the PROCEED trial and will<br \/>\n      provide investigators with instructions to conclude the trial. The study<br \/>\n      results will be presented in a future scientific congress.\n    <\/p>\n<p>\n      \u201cAdvanced stage ovarian cancer is a difficult-to-treat disease with few<br \/>\n      options available, and we are disappointed by the outcome of this<br \/>\n      confirmatory study. We would like to thank our clinical investigators<br \/>\n      and especially the patients with platinum-resistant ovarian cancer who<br \/>\n      participated in the clinical studies for these investigational<br \/>\n      candidates,\u201d the Companies said.\n    <\/p>\n<p>\n      The randomized Phase 2b TARGET trial in non-small cell lung cancer<br \/>\n      (NSCLC) is ongoing. The Companies are awaiting maturation of the overall<br \/>\n      survival data later this year to help inform potential further<br \/>\n      development of the vintafolide and docetaxel combination in NSCLC.\n    <\/p>\n<p>\n      <b>About Merck<\/b>\n    <\/p>\n<p>\n      Today\u2019s Merck is a global healthcare leader working to help the world be<br \/>\n      well. Merck is known as MSD outside the United States and Canada.<br \/>\n      Through our prescription medicines, vaccines, biologic therapies, and<br \/>\n      consumer care and animal health products, we work with customers and<br \/>\n      operate in more than 140 countries to deliver innovative health<br \/>\n      solutions. We also demonstrate our commitment to increasing access to<br \/>\n      healthcare through far-reaching policies, programs and partnerships. For<br \/>\n      more information, visit <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&#038;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated&#038;esheet=50868939&#038;newsitemid=20140519006556&#038;lan=en-US&#038;anchor=vip2-msd.com\/merckcom-migrated&#038;index=1&#038;md5=aa1b16dbe1f6a39aa884915fb3ab9fd3\" rel=\"nofollow\">vip2-msd.com\/merckcom-migrated<\/a><br \/>\n      and connect with us on <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&#038;url=https%3A%2F%2Ftwitter.com%2Fmerck&#038;esheet=50868939&#038;newsitemid=20140519006556&#038;lan=en-US&#038;anchor=Twitter&#038;index=2&#038;md5=82017089c7e21aa3a7857ea2a07574d3\" rel=\"nofollow\">Twitter<\/a>,<br \/>\n      <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&#038;url=http%3A%2F%2Fwww.facebook.com%2Fmerckbewell&#038;esheet=50868939&#038;newsitemid=20140519006556&#038;lan=en-US&#038;anchor=Facebook&#038;index=3&#038;md5=8b347de5186792aefa7674809ebcd634\" rel=\"nofollow\">Facebook<\/a><br \/>\n      and <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&#038;url=http%3A%2F%2Fwww.youtube.com%2Fmerck&#038;esheet=50868939&#038;newsitemid=20140519006556&#038;lan=en-US&#038;anchor=YouTube&#038;index=4&#038;md5=0efcfe9db10f00c95a673dde60ebdd75\" rel=\"nofollow\">YouTube<\/a>.\n    <\/p>\n<p>\n      <b>About Endocyte<\/b>\n    <\/p>\n<p>\n      Endocyte is a biopharmaceutical company and leader in developing<br \/>\n      targeted small molecule drug conjugates (SMDCs) and companion imaging<br \/>\n      agents for personalized therapy in cancer and other serious diseases.<br \/>\n      Endocyte uses its proprietary technology to create novel SMDCs and<br \/>\n      companion imaging agents for personalized targeted therapies. The<br \/>\n      company&#8217;s SMDCs actively target receptors that are expressed or<br \/>\n      over-expressed on diseased cells, relative to healthy cells. This<br \/>\n      targeted approach is designed to enable the treatment of patients with<br \/>\n      highly potent drugs into these cells. The companion imaging agents are<br \/>\n      designed to identify patients whose disease expresses the molecular<br \/>\n      target of the therapy and who therefore may be more likely to benefit<br \/>\n      from treatment. For more information, visit <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&#038;url=http%3A%2F%2Fwww.endocyte.com&#038;esheet=50868939&#038;newsitemid=20140519006556&#038;lan=en-US&#038;anchor=http%3A%2F%2Fwww.endocyte.com&#038;index=5&#038;md5=c9ebdd0bfc38140f29b539b2ef1bd589\" rel=\"nofollow\">http:\/\/www.endocyte.com<\/a>.\n    <\/p>\n<p>\n      <b>Merck Forward-Looking Statement<\/b>\n    <\/p>\n<p>\n      This news release includes \u201cforward-looking statements\u201d within the<br \/>\n      meaning of the safe harbor provisions of the United States Private<br \/>\n      Securities Litigation Reform Act of 1995. These statements are based<br \/>\n      upon the current beliefs and expectations of Merck\u2019s management and are<br \/>\n      subject to significant risks and uncertainties. There can be no<br \/>\n      guarantees with respect to pipeline products that the products will<br \/>\n      receive the necessary regulatory approvals or that they will prove to be<br \/>\n      commercially successful. If underlying assumptions prove inaccurate or<br \/>\n      risks or uncertainties materialize, actual results may differ materially<br \/>\n      from those set forth in the forward-looking statements.\n    <\/p>\n<p>\n      Risks and uncertainties include but are not limited to, general industry<br \/>\n      conditions and competition; general economic factors, including interest<br \/>\n      rate and currency exchange rate fluctuations; the impact of<br \/>\n      pharmaceutical industry regulation and health care legislation in the<br \/>\n      United States and internationally; global trends toward health care cost<br \/>\n      containment; technological advances, new products and patents attained<br \/>\n      by competitors; challenges inherent in new product development,<br \/>\n      including obtaining regulatory approval; Merck\u2019s ability to accurately<br \/>\n      predict future market conditions; manufacturing difficulties or delays;<br \/>\n      financial instability of international economies and sovereign risk;<br \/>\n      dependence on the effectiveness of Merck\u2019s patents and other protections<br \/>\n      for innovative products; and the exposure to litigation, including<br \/>\n      patent litigation, and\/or regulatory actions.\n    <\/p>\n<p>\n      Merck undertakes no obligation to publicly update any forward-looking<br \/>\n      statement, whether as a result of new information, future events or<br \/>\n      otherwise. Additional factors that could cause results to differ<br \/>\n      materially from those described in the forward-looking statements can be<br \/>\n      found in Merck\u2019s 2013 Annual Report on Form 10-K and the company\u2019s other<br \/>\n      filings with the Securities and Exchange Commission (SEC) available at<br \/>\n      the SEC\u2019s Internet site (<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&#038;url=http%3A%2F%2Fwww.sec.gov%2F&#038;esheet=50868939&#038;newsitemid=20140519006556&#038;lan=en-US&#038;anchor=www.sec.gov&#038;index=6&#038;md5=f7f3d19ee5dc19d028ef78af0d0bf84c\" rel=\"nofollow\">www.sec.gov<\/a>).\n    <\/p>\n<p>\n      <b>Endocyte Forward-Looking Statement<\/b>\n    <\/p>\n<p>\n      Certain of the statements made in this press release are forward<br \/>\n      looking, such as those, among others, relating to the company&#8217;s<br \/>\n      expectations for seeking regulatory approval and commercial launch of<br \/>\n      its products, including any conditional marketing authorization from the<br \/>\n      EMA, initiation of future clinical trials, and expectations for the<br \/>\n      receipt of milestones, royalties or other profits from the company\u2019s<br \/>\n      partnership with Merck. Actual results or developments may differ<br \/>\n      materially from those projected or implied in these forward-looking<br \/>\n      statements. Factors that may cause such a difference include risks that<br \/>\n      the company may experience delays in the completion of its clinical<br \/>\n      trials (whether caused by competition, adverse events, patient<br \/>\n      enrollment rates, unavailability of clinical trial materials, regulatory<br \/>\n      issues or other factors); risks that data from its clinical trials may<br \/>\n      not be indicative of subsequent clinical trial results; risks related to<br \/>\n      the safety and efficacy of the company&#8217;s product candidates, the goals<br \/>\n      of its development activities, estimates of the potential markets for<br \/>\n      its product candidates, estimates of the capacity of manufacturing and<br \/>\n      other facilities required to support its product candidates, projected<br \/>\n      cash needs, and expected financial results. More information about the<br \/>\n      risks and uncertainties faced by Endocyte, Inc. is contained in the<br \/>\n      company&#8217;s periodic reports filed with the Securities and Exchange<br \/>\n      Commission. Endocyte, Inc. disclaims any intention or obligation to<br \/>\n      update or revise any forward-looking statements, whether as a result of<br \/>\n      new information, future events or otherwise.\n    <\/p>\n<p class=\"bwalignc\">\n<p><img decoding=\"async\" alt=\"\" src=\"\/\/cts.businesswire.com\/ct\/CT?id=bwnews&#038;sty=20140519006556r1&#038;sid=hq1sf1&#038;distro=nx\" \/><span class=\"bwct31415\"\/><\/span><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">Photos\/Multimedia Gallery Available: <\/span><span id=\"mmgallerylink-link\"><a href=\"http:\/\/www.businesswire.com\/multimedia\/home\/20140519006556\/en\/\" rel=\"nofollow\">http:\/\/www.businesswire.com\/multimedia\/home\/20140519006556\/en\/<\/a><\/span><\/p>\n<p>       Merck<br \/>Media:<br \/>Ian McConnell, +1 908-423-3046<br \/>or<br \/>Claire        Mulhearn, +1 908-423-7425<br \/>or<br \/>Investors:<br \/>Carol Ferguson,        +1 908-423-4465<br \/>or<br \/>Justin Holko, +1 908-423-5088<br \/>or<br \/>Endocyte<br \/>Media:<br \/>Martina        Schwarzkopf, +1 212-845-4292<br \/>or<br \/>Tony Russo, +1 212-845-4251<br \/>or<br \/>Investors:<br \/>Stephanie        Ascher, +1 212-362-1200     <\/p>\n","protected":false},"excerpt":{"rendered":"<p>Merck (NYSE:MRK), known as MSD outside the United States and Canada, and Endocyte, Inc. (NASDAQ:ECYT), today announced the withdrawal of conditional marketing authorization applications (CMA) from the European Medicines Agency (EMA) for vintafolide and companion imaging components, imaging agent etarfolatide and intravenous (IV) folic acid, for the treatment of adult patients with folate receptor-positive, platinum-resistant ovarian cancer, in combination with pegylated liposomal doxorubicin (PLD). The Companies\u2019 decision was based on further review of interim data from the PROCEED trial. Study enrollment was suspended earlier this month based on the Data Safety Monitoring Board\u2019s (DSMB) recommendation that the study be stopped because vintafolide in combination with PLD versus PLD alone did not meet the pre-specified criteria for progression-free survival to allow continuation of the study. The DSMB did not identify any safety concerns for the patients enrolled in the PROCEED trial.<\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"bdl_company_name":[],"bdl_item_external_link":[],"inpsyde_pem_expiration_date":[],"inpsyde_pem_expiration_action":[],"footnotes":""},"tags":[53,64,137,138,289],"class_list":["post-744977","news_item","type-news_item","status-publish","hentry","tag-corporate-news","tag-latest-news","tag-oncology","tag-oncology-newsroom","tag-press-release"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Merck and Endocyte Announce Withdrawal of Conditional Marketing Authorization Applications for Vintafolide and Companion Imaging Components, Etarfolatide and Intravenous (IV) Folic Acid in Europe - Merck.com<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-and-endocyte-announce-withdrawal-of-conditional-marketing-authorization-applications-for-vintafolide-and-companion-imaging-components-etarfolatide-and-intravenous-iv-folic-acid-in-europe\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Merck and Endocyte Announce Withdrawal of Conditional Marketing Authorization Applications for Vintafolide and Companion Imaging Components, Etarfolatide and Intravenous (IV) Folic Acid in Europe - Merck.com\" \/>\n<meta property=\"og:description\" content=\"Merck (NYSE:MRK), known as MSD outside the United States and Canada, and Endocyte, Inc. (NASDAQ:ECYT), today announced the withdrawal of conditional marketing authorization applications (CMA) from the European Medicines Agency (EMA) for vintafolide and companion imaging components, imaging agent etarfolatide and intravenous (IV) folic acid, for the treatment of adult patients with folate receptor-positive, platinum-resistant ovarian cancer, in combination with pegylated liposomal doxorubicin (PLD). The Companies\u2019 decision was based on further review of interim data from the PROCEED trial. Study enrollment was suspended earlier this month based on the Data Safety Monitoring Board\u2019s (DSMB) recommendation that the study be stopped because vintafolide in combination with PLD versus PLD alone did not meet the pre-specified criteria for progression-free survival to allow continuation of the study. The DSMB did not identify any safety concerns for the patients enrolled in the PROCEED trial.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-and-endocyte-announce-withdrawal-of-conditional-marketing-authorization-applications-for-vintafolide-and-companion-imaging-components-etarfolatide-and-intravenous-iv-folic-acid-in-europe\/\" \/>\n<meta property=\"og:site_name\" content=\"Merck.com\" \/>\n<meta property=\"article:modified_time\" content=\"2023-03-22T04:04:55+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png\" \/>\n\t<meta property=\"og:image:width\" content=\"3056\" \/>\n\t<meta property=\"og:image:height\" content=\"1380\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-and-endocyte-announce-withdrawal-of-conditional-marketing-authorization-applications-for-vintafolide-and-companion-imaging-components-etarfolatide-and-intravenous-iv-folic-acid-in-europe\\\/\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-and-endocyte-announce-withdrawal-of-conditional-marketing-authorization-applications-for-vintafolide-and-companion-imaging-components-etarfolatide-and-intravenous-iv-folic-acid-in-europe\\\/\",\"name\":\"Merck and Endocyte Announce Withdrawal of Conditional Marketing Authorization Applications for Vintafolide and Companion Imaging Components, Etarfolatide and Intravenous (IV) Folic Acid in Europe - Merck.com\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\"},\"datePublished\":\"2014-05-19T16:00:00+00:00\",\"dateModified\":\"2023-03-22T04:04:55+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-and-endocyte-announce-withdrawal-of-conditional-marketing-authorization-applications-for-vintafolide-and-companion-imaging-components-etarfolatide-and-intravenous-iv-folic-acid-in-europe\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-and-endocyte-announce-withdrawal-of-conditional-marketing-authorization-applications-for-vintafolide-and-companion-imaging-components-etarfolatide-and-intravenous-iv-folic-acid-in-europe\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-and-endocyte-announce-withdrawal-of-conditional-marketing-authorization-applications-for-vintafolide-and-companion-imaging-components-etarfolatide-and-intravenous-iv-folic-acid-in-europe\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"News\",\"item\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news-archive\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Merck and Endocyte Announce Withdrawal of Conditional Marketing Authorization Applications for Vintafolide and Companion Imaging Components, Etarfolatide and Intravenous (IV) Folic Acid in Europe\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/\",\"name\":\"Merck.com\",\"description\":\"Just another vip-msd.com site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Merck and Endocyte Announce Withdrawal of Conditional Marketing Authorization Applications for Vintafolide and Companion Imaging Components, Etarfolatide and Intravenous (IV) Folic Acid in Europe - Merck.com","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-and-endocyte-announce-withdrawal-of-conditional-marketing-authorization-applications-for-vintafolide-and-companion-imaging-components-etarfolatide-and-intravenous-iv-folic-acid-in-europe\/","og_locale":"en_US","og_type":"article","og_title":"Merck and Endocyte Announce Withdrawal of Conditional Marketing Authorization Applications for Vintafolide and Companion Imaging Components, Etarfolatide and Intravenous (IV) Folic Acid in Europe - Merck.com","og_description":"Merck (NYSE:MRK), known as MSD outside the United States and Canada, and Endocyte, Inc. (NASDAQ:ECYT), today announced the withdrawal of conditional marketing authorization applications (CMA) from the European Medicines Agency (EMA) for vintafolide and companion imaging components, imaging agent etarfolatide and intravenous (IV) folic acid, for the treatment of adult patients with folate receptor-positive, platinum-resistant ovarian cancer, in combination with pegylated liposomal doxorubicin (PLD). The Companies\u2019 decision was based on further review of interim data from the PROCEED trial. Study enrollment was suspended earlier this month based on the Data Safety Monitoring Board\u2019s (DSMB) recommendation that the study be stopped because vintafolide in combination with PLD versus PLD alone did not meet the pre-specified criteria for progression-free survival to allow continuation of the study. The DSMB did not identify any safety concerns for the patients enrolled in the PROCEED trial.","og_url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-and-endocyte-announce-withdrawal-of-conditional-marketing-authorization-applications-for-vintafolide-and-companion-imaging-components-etarfolatide-and-intravenous-iv-folic-acid-in-europe\/","og_site_name":"Merck.com","article_modified_time":"2023-03-22T04:04:55+00:00","og_image":[{"width":3056,"height":1380,"url":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-and-endocyte-announce-withdrawal-of-conditional-marketing-authorization-applications-for-vintafolide-and-companion-imaging-components-etarfolatide-and-intravenous-iv-folic-acid-in-europe\/","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-and-endocyte-announce-withdrawal-of-conditional-marketing-authorization-applications-for-vintafolide-and-companion-imaging-components-etarfolatide-and-intravenous-iv-folic-acid-in-europe\/","name":"Merck and Endocyte Announce Withdrawal of Conditional Marketing Authorization Applications for Vintafolide and Companion Imaging Components, Etarfolatide and Intravenous (IV) Folic Acid in Europe - Merck.com","isPartOf":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website"},"datePublished":"2014-05-19T16:00:00+00:00","dateModified":"2023-03-22T04:04:55+00:00","breadcrumb":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-and-endocyte-announce-withdrawal-of-conditional-marketing-authorization-applications-for-vintafolide-and-companion-imaging-components-etarfolatide-and-intravenous-iv-folic-acid-in-europe\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-and-endocyte-announce-withdrawal-of-conditional-marketing-authorization-applications-for-vintafolide-and-companion-imaging-components-etarfolatide-and-intravenous-iv-folic-acid-in-europe\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-and-endocyte-announce-withdrawal-of-conditional-marketing-authorization-applications-for-vintafolide-and-companion-imaging-components-etarfolatide-and-intravenous-iv-folic-acid-in-europe\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"News","item":"https:\/\/vip2-msd.com\/merckcom-migrated\/news-archive\/"},{"@type":"ListItem","position":2,"name":"Merck and Endocyte Announce Withdrawal of Conditional Marketing Authorization Applications for Vintafolide and Companion Imaging Components, Etarfolatide and Intravenous (IV) Folic Acid in Europe"}]},{"@type":"WebSite","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/","name":"Merck.com","description":"Just another vip-msd.com site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/vip2-msd.com\/merckcom-migrated\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":{"news_item_workflow_id":"56c33ff7-5f59-4d43-b348-0370f965b323","news_item_aria_label":"","media_files":[{"path":"https:\/\/s2.q4cdn.com\/584635680\/files\/doc_events\/2014\/05\/1\/logo_merck-logo.jpg","size":"13027","File Upload":""},{"path":"https:\/\/s2.q4cdn.com\/584635680\/files\/doc_events\/2014\/05\/1\/Endocyte.jpg","size":"18866","File Upload":""}],"document_path":"","file":""},"_links":{"self":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/744977","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item"}],"about":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/types\/news_item"}],"version-history":[{"count":0,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/744977\/revisions"}],"wp:attachment":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/media?parent=744977"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/tags?post=744977"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}